Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 result for satralizumab

  1. Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) (TA960)

    NICE is unable to make a recommendation on satralizumab (Enspryng) for preventing relapses in neuromyelitis optica spectrum disorders in adults

    Sections for TA960